AZD 3839

Drug Profile

AZD 3839

Alternative Names: AZD3839

Latest Information Update: 06 Aug 2012

Price : $50

At a glance

  • Originator Astex Therapeutics; AstraZeneca
  • Developer AstraZeneca
  • Class Antidementias; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 30 Jun 2012 Discontinued - Phase-I for Alzheimer's disease in United Kingdom (PO)
  • 30 Nov 2011 AstraZeneca completes a phase I trial in Healthy volunteers in United Kingdom (NCT01348737)
  • 21 Jun 2011 Phase-I clinical trials in Alzheimer's disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top